Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study
Titel:
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study
Auteur:
Morales, Serafín Lorenzo, Antonio Ramos, Manuel Ballesteros, Pedro Méndez, Miguel Almanza, Concepción Castellanos, Javier Moreno-Nogueira, José Andrés Casal, Joaquín Lizón, José Oltra, Amparo Frau, Adolfo Machengs, Ignacio Galán, Antonio Belón, Joaquín Llorca, Cristina